Astellas Pharma Inc. (TYO: 4503) announced its global financial results for the second quarter of fiscal year 2026 (covering April 1, 2026 to September 30, 2026), reporting revenue of JPY 1,270.9 billion, a 23.4 % year‑on‑year increase, and core operating profit of JPY 424.9 billion, up 50.3 % year‑on‑year, driven by the strong performance of Xtandi, Padcev, and its broader strategic brand portfolio.
Financial Highlights – Q2 FY2026 (Apr 1 – Sep 30, 2026)
| Item | Result | YoY Change |
|---|---|---|
| Revenue | JPY 1,270.9 billion | +23.4 % |
| Core Operating Profit | JPY 424.9 billion | +50.3 % |
| Core Operating Margin | ≈ 33.4 % (derived) | Profit growth more than double revenue growth |
| China Commercial Region Revenue | JPY 68.9 billion | +38.5 % |
Strategic Brand Performance
| Product | Molecule | Sales (JPY) | YoY Growth |
|---|---|---|---|
| Xtandi | Enzalutamide | 533.7 billion | +11.9 % |
| Padcev | Enfortumab vedotin | 158.3 billion | +54.5 % |
| Izelvay | Avacincaptad pegol | 56.2 billion | +64.5 % |
| Vyloy | Zolbetuximab | 45.9 billion | +72.7 % |
| Xospata | Gilteritinib | 42.9 billion | +24.5 % |
| Veozah | Fezolinetant | 30.7 billion | +33.8 % |
| Strategic Brands – Total | – | 333.9 billion | +51.4 % |
Portfolio Profile
- Xtandi (enzalutamide): The company’s largest revenue contributor at JPY 533.7 billion, an androgen receptor inhibitor anchoring Astellas’s urology‑oncology franchise with continued double‑digit growth of 11.9 %.
- Padcev (enfortumab vedotin): A flagship antibody–drug conjugate in urothelial cancer, delivering JPY 158.3 billion in sales, up 54.5 % year‑on‑year — the largest growth engine within the strategic brand portfolio.
- Izelvay (avacincaptad pegol): Recorded JPY 56.2 billion, up 64.5 %, reflecting strong uptake momentum.
- Vyloy (zolbetuximab): The fastest‑growing strategic brand at +72.7 %, reaching JPY 45.9 billion as a targeted therapy in gastric cancer.
- Veozah (fezolinetant): Posted JPY 30.7 billion, up 33.8 %, in the non‑hormonal women’s health space.
- Xospata (gilteritinib): A precision‑medicine asset in acute myeloid leukemia, contributing JPY 42.9 billion, up 24.5 %.
- Oncology & Specialty Core: The results were driven by the strong potential demonstrated by the company’s oncology and specialty medicine portfolios, per the announcement.
Regional Spotlight – China Commercial Region
- Revenue: The China Commercial Region achieved JPY 68.9 billion, up 38.5 % year‑on‑year — outpacing the company’s global revenue growth rate of 23.4 %.
- Contribution: China contributed significantly to global performance growth, highlighting the region’s rising strategic weight within Astellas’s global commercial footprint.
Market Impact & Outlook
- Operating Leverage: With core operating profit up 50.3 % against 23.4 % revenue growth, Astellas demonstrated substantial margin expansion — core operating margin of approximately 33.4 %.
- Portfolio Rotation Working: The +51.4 % surge in strategic brand sales to JPY 333.9 billion signals that newer growth brands are successfully complementing the mature Xtandi franchise.
- Diversified Growth Engines: Four strategic brands grew faster than 33 % year‑on‑year (Padcev, Izelvay, Vyloy, Veozah), reducing dependence on any single product.
- Emerging‑Market Momentum: China’s 38.5 % growth positions the region as a key expansion lever alongside the U.S. and Japan.
- Watch Items: Full‑year guidance revisions, Xtandi patent‑cliff management, continued ramp of Vyloy, Izelvay, and Veozah, and sustained China growth into the second half of FY2026.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding Astellas Pharma’s business outlook, brand growth trajectories, and regional performance. Actual results may differ due to risks including market competition, pricing and reimbursement dynamics, foreign‑exchange movements, regulatory developments, intellectual‑property expirations, and changes in demand across key markets. Figures presented are drawn from the company’s Q2 FY2026 results announcement for the period April 1 – September 30, 2026.-Fineline Info & Tech
